Cystic fibrosis year in review 2019: Section 1 CFTR modulators

Adrienne P. Savant; Susanna A. McColley

doi:10.1002/ppul.25039

Cystic fibrosis year in review 2019: Section 1 CFTR modulators

Adrienne P. Savant^*, Susanna A. McColley

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

During the year 2019, research and case reports/series in the field of cystic fibrosis (CF) were in abundance. To adequately address the large body of CF research published during 2019, the CF year in review will be divided into three sections. This report is the first section, focusing specifically on new research related to cystic fibrosis transmembrane conductance regulator modulator therapy. Additional sections will concentrate on pulmonary and infections research and the multisystem effects of CF. It is an exciting time to be providing care for patients and their families with CF with all the exciting new discoveries that will be shared in these reviews.

Original language	English (US)
Pages (from-to)	3236-3242
Number of pages	7
Journal	Pediatric Pulmonology
Volume	55
Issue number	12
DOIs	https://doi.org/10.1002/ppul.25039
State	Published - Dec 2020

Keywords

clinical trials
cystic fibrosis
evidence-based medicine and outcomes

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pulmonary and Respiratory Medicine

Access to Document

10.1002/ppul.25039

Cite this

@article{840d5cacf8e348d28b70313f43dd4d8f,

title = "Cystic fibrosis year in review 2019: Section 1 CFTR modulators",

abstract = "During the year 2019, research and case reports/series in the field of cystic fibrosis (CF) were in abundance. To adequately address the large body of CF research published during 2019, the CF year in review will be divided into three sections. This report is the first section, focusing specifically on new research related to cystic fibrosis transmembrane conductance regulator modulator therapy. Additional sections will concentrate on pulmonary and infections research and the multisystem effects of CF. It is an exciting time to be providing care for patients and their families with CF with all the exciting new discoveries that will be shared in these reviews.",

keywords = "clinical trials, cystic fibrosis, evidence-based medicine and outcomes",

author = "Savant, {Adrienne P.} and McColley, {Susanna A.}",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2020",

month = dec,

doi = "10.1002/ppul.25039",

language = "English (US)",

volume = "55",

pages = "3236--3242",

journal = "Pediatric Pulmonology",

issn = "8755-6863",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - Cystic fibrosis year in review 2019

T2 - Section 1 CFTR modulators

AU - Savant, Adrienne P.

AU - McColley, Susanna A.

PY - 2020/12

Y1 - 2020/12

N2 - During the year 2019, research and case reports/series in the field of cystic fibrosis (CF) were in abundance. To adequately address the large body of CF research published during 2019, the CF year in review will be divided into three sections. This report is the first section, focusing specifically on new research related to cystic fibrosis transmembrane conductance regulator modulator therapy. Additional sections will concentrate on pulmonary and infections research and the multisystem effects of CF. It is an exciting time to be providing care for patients and their families with CF with all the exciting new discoveries that will be shared in these reviews.

AB - During the year 2019, research and case reports/series in the field of cystic fibrosis (CF) were in abundance. To adequately address the large body of CF research published during 2019, the CF year in review will be divided into three sections. This report is the first section, focusing specifically on new research related to cystic fibrosis transmembrane conductance regulator modulator therapy. Additional sections will concentrate on pulmonary and infections research and the multisystem effects of CF. It is an exciting time to be providing care for patients and their families with CF with all the exciting new discoveries that will be shared in these reviews.

KW - clinical trials

KW - cystic fibrosis

KW - evidence-based medicine and outcomes

UR - http://www.scopus.com/inward/record.url?scp=85090061285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090061285&partnerID=8YFLogxK

U2 - 10.1002/ppul.25039

DO - 10.1002/ppul.25039

M3 - Review article

C2 - 32833326

AN - SCOPUS:85090061285

SN - 8755-6863

VL - 55

SP - 3236

EP - 3242

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

IS - 12

ER -

Cystic fibrosis year in review 2019: Section 1 CFTR modulators

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this